Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01MH065571 | U.S. NIH Grant/Contract | View source | |
| R01MH065707 | U.S. NIH Grant/Contract | View source | |
| R01MH065578 | U.S. NIH Grant/Contract | View source | |
| R01MH065588 | U.S. NIH Grant/Contract | View source | |
| R01MH065554 | U.S. NIH Grant/Contract | View source | |
| R01MH065562 | U.S. NIH Grant/Contract | View source | |
| DNBBS 7G-GRR |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Mental Health (NIMH) | NIH |
This is a study of the genetic basis of brain dysfunction in people with schizophrenia.
Schizophrenia is a disabling disorder that is associated with specific inheritable neurobiologic deficits. These deficits can cause problems with memory, visual attention, information processing, and other aspects of daily living. Understanding the genetic components of these deficits in people with schizophrenia and their unaffected family members may help uncover the neurobiological basis, risk factors, and heritability of the disease. In addition, the information may serve to create more effective treatments and possibly a cure for the disease. This study will serve to provide information about the genetic basis of known inherited neurobiological deficits in people with schizophrenia. In turn, this may guide further studies on the genetics of schizophrenia.
Participants will attend 2 study visits, each of which will last approximately 4 hours. The first will include blood tests and diagnostic interviews of participating families to evaluate the presence of schizophrenic symptoms. The second study visit will entail four neurocognitive and neurophysiological tests. Participants will first have a pre-pulse inhibition test, which uses electrodes to measure eye blinking. Electrodes will also be placed on participants' head, ears, and around their eyes to measure brain waves. Next, participants will undergo an oculomotor test, during which they will wear glasses fitted with sensors that record eye movement. Participants will then be asked to repeat a list of words, letters, and numbers read by a researcher. Last, participants will undergo a computerized performance test requiring them to watch the computer screen and click a mouse whenever they see a number between 0 and 9. Each study visit will take approximately 4 hours.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| percent inhibition to the 60 msec prepulse, P50 suppression, proportion of correct saccades, d, number correct in the reorder condition, the total recall score | The primary outcome measure for each endophenotype is as follows: for prepulse inhibition (PPI) the primary measure is the percent inhibition to the 60 msec prepulse; for P50 suppression it is the difference in amplitude between the test and conditioning stimuli; for antisaccade it is the proportion of correct saccades; for the DS-CPT it is (d') which is based on correct target detections and incorrect responses to nontargets; for LNS it is the number correct in the reorder condition; for CVLT it is the total recall score summed across 5 trials. | Upon entry to the study |
Not provided
Not provided
Inclusion Criteria for Participating Families:
Exclusion Criteria:
Not provided
Not provided
Not provided
The subject population will include schizophrenia probands (12 per site per year), first degree relatives (36 per site per year) and normal comparison subjects (15 per site per year). The proband must meet the diagnosis of schizophrenia by DSM-IV criteria. There must be at least one parent and one unaffected sibling in the pedigree. Therefore a total of 315 subjects will be enrolled at each site each year with a total of 2205 enrolled across all 7 sites. Schizophrenia probands and normal subjects will be between 18 and 65 years of age. Exclusion criteria include visual or hearing impairments, history of head trauma, organic brain dysfunction, neurological disease, and significant drug or alcohol use and for controls, significant psychiatric history and/or current use of psychotropic medications. We will include equal numbers of men and women and all appropriate subjects willing to participate regardless of ethnic background.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Braff, MD | University of California, San Diego | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California Los Angeles | Los Angeles | California | 90073 | United States | ||
| University of California, San Diego |
Not provided
| Label | URL |
|---|---|
| Click here for more information on the Schizophrenia Research Program | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| D000092862 | Psychological Well-Being |
| D011618 | Psychotic Disorders |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
| D010549 | Personal Satisfaction |
| D001519 | Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Whole blood was sent to the Cell Repository at Rutgers toestablish cell lines.
| San Diego |
| California |
| 92103 |
| United States |
| University of Colorado Health Sciences Center | Denver | Colorado | 80220 | United States |
| Harvard University | Boston | Massachusetts | 02115 | United States |
| Mount Sinai School of Medicine | New York | New York | 10029 | United States |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States |
| University of Washington and VA Puget Sound Health Care System | Seattle | Washington | 98108 | United States |